Table Graph
   

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) - versus placebo - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

symptomatic Covid-19 0.24 [0.18, 0.32]< 10%1 study (1/-)100.0 %NAnot evaluable important-

safety endpoints 00

adverse events 1.62 [1.54, 1.70]< 10%2 studies (2/-)0.0 %NAnot evaluable non important-
ATE (Myocardial infarction or ischemic stroke) 0.12 [0.01, 2.77]< 10%1 study (1/-)90.3 %NAnot evaluable non important-
Guillain-Barré syndrome 1.00 [0.03, 29.81]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
intracranial hemorrhage 0.41 [0.03, 6.54]< 10%2 studies (2/-)73.5 %NAnot evaluable non important-
ischemic stroke 0.18 [0.02, 2.07]< 10%2 studies (2/-)91.4 %NAnot evaluable non important-
Myocardial infarction 0.28 [0.02, 3.68]< 10%2 studies (2/-)83.1 %NAnot evaluable non important-
pulmonary embolism 0.41 [0.03, 6.54]< 10%2 studies (2/-)73.5 %NAnot evaluable non important-
serious adverse events (SAE), any 0.93 [0.61, 1.41]< 11%2 studies (2/-)63.7 %NAnot evaluable non important-

AE of interest endpoints 00

Bell's palsy 1.00 [0.03, 29.81]< 10%1 study (1/-)50.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons